OrthoPediatrics (NASDAQ:KIDS) had its price objective upped by investment analysts at Piper Sandler from $55.00 to $62.00 in a research report issued on Tuesday, The Fly reports. Piper Sandler’s target price suggests a potential upside of 28.07% from the company’s previous close.
Separately, Zacks Investment Research cut OrthoPediatrics from a “hold” rating to a “sell” rating in a research report on Friday, March 12th. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company’s stock. OrthoPediatrics has a consensus rating of “Buy” and an average price target of $54.50.
NASDAQ KIDS opened at $48.41 on Tuesday. The company has a market cap of $951.64 million, a PE ratio of -33.62 and a beta of 0.67. OrthoPediatrics has a 12 month low of $38.01 and a 12 month high of $57.42. The stock has a 50 day moving average of $50.21 and a 200-day moving average of $46.70.
In related news, Director Bernie B. Berry III sold 3,136 shares of the firm’s stock in a transaction dated Wednesday, January 27th. The stock was sold at an average price of $51.73, for a total value of $162,225.28. Following the sale, the director now directly owns 40,481 shares of the company’s stock, valued at $2,094,082.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David R. Pelizzon acquired 3,700 shares of OrthoPediatrics stock in a transaction that occurred on Monday, March 15th. The stock was acquired at an average cost of $46.50 per share, for a total transaction of $172,050.00. Following the completion of the purchase, the director now directly owns 20,900 shares of the company’s stock, valued at $971,850. The disclosure for this purchase can be found here. Insiders sold 47,686 shares of company stock worth $2,589,408 in the last 90 days. 33.60% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Brown Capital Management LLC boosted its stake in shares of OrthoPediatrics by 5.4% during the fourth quarter. Brown Capital Management LLC now owns 1,634,004 shares of the company’s stock valued at $67,403,000 after purchasing an additional 84,209 shares in the last quarter. Brown Advisory Inc. lifted its stake in shares of OrthoPediatrics by 1.6% in the fourth quarter. Brown Advisory Inc. now owns 1,128,779 shares of the company’s stock worth $46,562,000 after acquiring an additional 17,794 shares during the period. Riverbridge Partners LLC lifted its stake in shares of OrthoPediatrics by 7.5% in the fourth quarter. Riverbridge Partners LLC now owns 1,062,463 shares of the company’s stock worth $43,827,000 after acquiring an additional 73,840 shares during the period. BlackRock Inc. lifted its stake in shares of OrthoPediatrics by 12.4% in the fourth quarter. BlackRock Inc. now owns 999,648 shares of the company’s stock worth $41,236,000 after acquiring an additional 110,290 shares during the period. Finally, Next Century Growth Investors LLC lifted its stake in shares of OrthoPediatrics by 17.5% in the fourth quarter. Next Century Growth Investors LLC now owns 582,775 shares of the company’s stock worth $24,039,000 after acquiring an additional 86,709 shares during the period. 71.74% of the stock is currently owned by institutional investors and hedge funds.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Featured Article: What is a Special Dividend?
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.